KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Change in Acquisitions & Divestments (2016 - 2025)

Nektar Therapeutics has reported Change in Acquisitions & Divestments over the past 16 years, most recently at $92.0 million for Q4 2025.

  • Quarterly results put Change in Acquisitions & Divestments at $92.0 million for Q4 2025, up 41.28% from a year ago — trailing twelve months through Dec 2025 was $284.7 million (down 16.36% YoY), and the annual figure for FY2025 was $284.7 million, down 16.36%.
  • Change in Acquisitions & Divestments for Q4 2025 was $92.0 million at Nektar Therapeutics, up from $54.8 million in the prior quarter.
  • Over the last five years, Change in Acquisitions & Divestments for NKTR hit a ceiling of $308.8 million in Q2 2021 and a floor of -$626.4 million in Q4 2022.
  • Median Change in Acquisitions & Divestments over the past 5 years was $152.3 million (2023), compared with a mean of $122.1 million.
  • Biggest five-year swings in Change in Acquisitions & Divestments: skyrocketed 177.58% in 2021 and later tumbled 337.04% in 2022.
  • Nektar Therapeutics' Change in Acquisitions & Divestments stood at $264.3 million in 2021, then tumbled by 337.04% to -$626.4 million in 2022, then surged by 124.98% to $156.5 million in 2023, then tumbled by 58.39% to $65.1 million in 2024, then surged by 41.28% to $92.0 million in 2025.
  • The last three reported values for Change in Acquisitions & Divestments were $92.0 million (Q4 2025), $54.8 million (Q3 2025), and $68.6 million (Q2 2025) per Business Quant data.